| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 61 | 2021 | 11039 | 3.620 |
Why?
|
| Prostate | 23 | 2020 | 1764 | 3.030 |
Why?
|
| Urinary Bladder Neoplasms | 26 | 2020 | 2229 | 2.940 |
Why?
|
| Kidney Neoplasms | 21 | 2020 | 4229 | 2.280 |
Why?
|
| Prostatectomy | 16 | 2019 | 1871 | 1.920 |
Why?
|
| Carcinoma, Renal Cell | 16 | 2020 | 3123 | 1.880 |
Why?
|
| Urinary Bladder | 7 | 2019 | 1171 | 1.330 |
Why?
|
| Urogenital Neoplasms | 2 | 2020 | 135 | 1.190 |
Why?
|
| Adenocarcinoma | 17 | 2020 | 6347 | 1.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2020 | 8425 | 1.120 |
Why?
|
| Urethral Neoplasms | 2 | 2020 | 40 | 1.120 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2019 | 798 | 1.030 |
Why?
|
| Cystectomy | 7 | 2019 | 682 | 1.000 |
Why?
|
| Prognosis | 43 | 2020 | 29010 | 0.940 |
Why?
|
| Prostate-Specific Antigen | 15 | 2019 | 2458 | 0.940 |
Why?
|
| Neoplasm Staging | 14 | 2020 | 11001 | 0.920 |
Why?
|
| Occupational Therapy | 2 | 2023 | 134 | 0.880 |
Why?
|
| MicroRNAs | 7 | 2019 | 3731 | 0.820 |
Why?
|
| Disease Progression | 21 | 2019 | 13256 | 0.730 |
Why?
|
| Aromatase | 3 | 2020 | 146 | 0.690 |
Why?
|
| Prostatic Hyperplasia | 9 | 2020 | 522 | 0.660 |
Why?
|
| Succinate Dehydrogenase | 2 | 2018 | 146 | 0.640 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 5 | 2020 | 62 | 0.630 |
Why?
|
| Activities of Daily Living | 6 | 2022 | 2414 | 0.630 |
Why?
|
| Male | 136 | 2021 | 349538 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2017 | 286 | 0.620 |
Why?
|
| Cushing Syndrome | 3 | 2010 | 249 | 0.620 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2020 | 143 | 0.620 |
Why?
|
| Calcium Signaling | 3 | 2019 | 721 | 0.620 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 83 | 0.600 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2017 | 20 | 0.600 |
Why?
|
| Neoplasm Invasiveness | 15 | 2021 | 3612 | 0.600 |
Why?
|
| Physical Therapy Modalities | 5 | 2019 | 547 | 0.580 |
Why?
|
| Hydrogen | 1 | 2017 | 164 | 0.580 |
Why?
|
| Immunohistochemistry | 15 | 2019 | 11363 | 0.560 |
Why?
|
| Magnetic Resonance Spectroscopy | 10 | 2019 | 3760 | 0.550 |
Why?
|
| Biopsy | 11 | 2019 | 6756 | 0.520 |
Why?
|
| Keratinocytes | 4 | 2019 | 797 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2018 | 9185 | 0.520 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 313 | 0.520 |
Why?
|
| Disulfides | 1 | 2017 | 457 | 0.520 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2015 | 104 | 0.520 |
Why?
|
| Apoptosis | 12 | 2020 | 9715 | 0.500 |
Why?
|
| Hematuria | 2 | 2013 | 235 | 0.500 |
Why?
|
| Humans | 169 | 2023 | 742088 | 0.490 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2006 | 162 | 0.480 |
Why?
|
| Lymphatic Metastasis | 3 | 2020 | 2906 | 0.480 |
Why?
|
| Muscle, Smooth | 3 | 2016 | 933 | 0.470 |
Why?
|
| Aged | 66 | 2022 | 162944 | 0.470 |
Why?
|
| Middle Aged | 73 | 2021 | 213127 | 0.460 |
Why?
|
| Metabolomics | 6 | 2019 | 1467 | 0.460 |
Why?
|
| Cadmium | 2 | 2013 | 212 | 0.450 |
Why?
|
| Cell Proliferation | 18 | 2020 | 10472 | 0.450 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 1483 | 0.450 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2018 | 1158 | 0.440 |
Why?
|
| Carcinoma, Ductal | 1 | 2013 | 101 | 0.440 |
Why?
|
| Upper Extremity | 5 | 2019 | 648 | 0.430 |
Why?
|
| Penile Neoplasms | 1 | 2014 | 159 | 0.420 |
Why?
|
| Taiwan | 9 | 2020 | 496 | 0.420 |
Why?
|
| RNA Interference | 5 | 2017 | 2890 | 0.410 |
Why?
|
| Urothelium | 3 | 2020 | 277 | 0.410 |
Why?
|
| Cell Line, Tumor | 21 | 2020 | 16665 | 0.410 |
Why?
|
| Carcinoma, Small Cell | 2 | 2015 | 420 | 0.410 |
Why?
|
| Survival Rate | 13 | 2020 | 12773 | 0.400 |
Why?
|
| Angiomyolipoma | 4 | 2020 | 186 | 0.400 |
Why?
|
| Disease-Free Survival | 11 | 2019 | 6891 | 0.400 |
Why?
|
| Diagnosis, Differential | 12 | 2020 | 12958 | 0.390 |
Why?
|
| Racemases and Epimerases | 4 | 2004 | 113 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2018 | 6534 | 0.390 |
Why?
|
| Urethra | 2 | 2016 | 408 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2017 | 3502 | 0.390 |
Why?
|
| Stroke | 11 | 2019 | 9963 | 0.380 |
Why?
|
| Reactive Oxygen Species | 8 | 2020 | 2077 | 0.370 |
Why?
|
| Receptors, Androgen | 8 | 2018 | 1057 | 0.370 |
Why?
|
| Lymphangioleiomyomatosis | 3 | 2019 | 210 | 0.370 |
Why?
|
| Membrane Proteins | 6 | 2020 | 7873 | 0.360 |
Why?
|
| Dermatitis, Atopic | 1 | 2017 | 653 | 0.360 |
Why?
|
| Oxidative Stress | 4 | 2018 | 3081 | 0.360 |
Why?
|
| Movement | 1 | 2017 | 1470 | 0.350 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 730 | 0.350 |
Why?
|
| DNA Methylation | 9 | 2020 | 4282 | 0.350 |
Why?
|
| Osteoporosis | 2 | 2017 | 1581 | 0.350 |
Why?
|
| Tuberous Sclerosis | 2 | 2014 | 1029 | 0.340 |
Why?
|
| Leuprolide | 1 | 2011 | 303 | 0.340 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 2633 | 0.340 |
Why?
|
| Microfilament Proteins | 1 | 2015 | 1152 | 0.340 |
Why?
|
| Paresis | 4 | 2019 | 179 | 0.340 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1097 | 0.340 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 1121 | 0.340 |
Why?
|
| Cell Movement | 8 | 2018 | 5212 | 0.330 |
Why?
|
| Tumor Microenvironment | 2 | 2019 | 3564 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2016 | 2842 | 0.330 |
Why?
|
| Ureteral Neoplasms | 1 | 2009 | 110 | 0.330 |
Why?
|
| Feedback, Sensory | 2 | 2019 | 55 | 0.330 |
Why?
|
| Kidney Pelvis | 1 | 2009 | 188 | 0.320 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2010 | 150 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 5 | 2018 | 933 | 0.320 |
Why?
|
| Acetyltransferases | 2 | 2010 | 234 | 0.320 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2020 | 424 | 0.320 |
Why?
|
| RNA, Messenger | 13 | 2020 | 13029 | 0.320 |
Why?
|
| Androstenes | 2 | 2020 | 169 | 0.310 |
Why?
|
| Laparoscopy | 3 | 2013 | 2121 | 0.300 |
Why?
|
| Stromal Cells | 5 | 2020 | 1353 | 0.300 |
Why?
|
| Androgen Antagonists | 3 | 2015 | 1350 | 0.290 |
Why?
|
| Proportional Hazards Models | 9 | 2018 | 12344 | 0.290 |
Why?
|
| Dextromethorphan | 1 | 2006 | 38 | 0.290 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2006 | 37 | 0.290 |
Why?
|
| Cyclins | 3 | 2007 | 601 | 0.290 |
Why?
|
| Ureter | 1 | 2009 | 374 | 0.290 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 546 | 0.290 |
Why?
|
| Signal Transduction | 16 | 2019 | 23387 | 0.280 |
Why?
|
| Neoplasm Metastasis | 7 | 2019 | 4839 | 0.280 |
Why?
|
| Ketorolac | 1 | 2006 | 77 | 0.280 |
Why?
|
| Diagnostic Imaging | 5 | 2018 | 3507 | 0.280 |
Why?
|
| Tissue Array Analysis | 3 | 2018 | 553 | 0.270 |
Why?
|
| Bone Neoplasms | 3 | 2019 | 2522 | 0.270 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2006 | 88 | 0.270 |
Why?
|
| Gastroenteritis | 2 | 2020 | 245 | 0.270 |
Why?
|
| Anemia | 1 | 2015 | 1499 | 0.260 |
Why?
|
| Female | 68 | 2020 | 379592 | 0.260 |
Why?
|
| Nuclear Receptor Coactivators | 2 | 2017 | 59 | 0.260 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4438 | 0.260 |
Why?
|
| Movement Disorders | 1 | 2008 | 444 | 0.260 |
Why?
|
| Retrospective Studies | 25 | 2023 | 77098 | 0.250 |
Why?
|
| Kidney | 3 | 2018 | 7167 | 0.250 |
Why?
|
| Adrenocortical Adenoma | 1 | 2005 | 48 | 0.250 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2006 | 253 | 0.240 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2004 | 76 | 0.240 |
Why?
|
| Radiation Injuries | 2 | 2016 | 1178 | 0.240 |
Why?
|
| Aged, 80 and over | 23 | 2020 | 57683 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2018 | 3557 | 0.240 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 2018 | 277 | 0.240 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2020 | 106 | 0.240 |
Why?
|
| Incidental Findings | 2 | 2019 | 688 | 0.240 |
Why?
|
| Gene Expression Profiling | 9 | 2019 | 9410 | 0.230 |
Why?
|
| Adult | 41 | 2020 | 213712 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 2906 | 0.230 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2009 | 670 | 0.220 |
Why?
|
| Brachytherapy | 1 | 2011 | 1246 | 0.220 |
Why?
|
| Urologic Neoplasms | 2 | 2020 | 316 | 0.220 |
Why?
|
| Pheochromocytoma | 1 | 2005 | 337 | 0.220 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 1509 | 0.220 |
Why?
|
| Cadherins | 3 | 2017 | 906 | 0.210 |
Why?
|
| Carcinoma, Papillary | 2 | 2020 | 781 | 0.210 |
Why?
|
| Parotid Diseases | 1 | 2002 | 46 | 0.210 |
Why?
|
| Survival Analysis | 5 | 2019 | 10248 | 0.210 |
Why?
|
| Adrenal Glands | 1 | 2005 | 547 | 0.210 |
Why?
|
| Histiocytosis, Sinus | 1 | 2002 | 47 | 0.210 |
Why?
|
| Telepathology | 2 | 2014 | 76 | 0.210 |
Why?
|
| Cell Cycle | 4 | 2018 | 2964 | 0.210 |
Why?
|
| Mass Spectrometry | 3 | 2017 | 2203 | 0.200 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2002 | 525 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2019 | 3471 | 0.200 |
Why?
|
| Disability Evaluation | 6 | 2020 | 1827 | 0.200 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 12242 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 5 | 2014 | 1799 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2015 | 2502 | 0.190 |
Why?
|
| Metformin | 2 | 2020 | 829 | 0.190 |
Why?
|
| Postural Balance | 2 | 2020 | 620 | 0.190 |
Why?
|
| Tumor Burden | 3 | 2015 | 1905 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2018 | 23320 | 0.190 |
Why?
|
| Receptors, CCR8 | 1 | 2020 | 27 | 0.190 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 2020 | 39 | 0.190 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 149 | 0.190 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2020 | 38 | 0.180 |
Why?
|
| Glycerophosphates | 1 | 2020 | 48 | 0.180 |
Why?
|
| Home Health Aides | 1 | 2020 | 15 | 0.180 |
Why?
|
| Alternative Splicing | 1 | 2005 | 1118 | 0.180 |
Why?
|
| Caliciviridae Infections | 1 | 2020 | 29 | 0.180 |
Why?
|
| Norovirus | 1 | 2020 | 35 | 0.180 |
Why?
|
| Loss of Heterozygosity | 5 | 2016 | 678 | 0.180 |
Why?
|
| Remote Consultation | 2 | 2014 | 238 | 0.180 |
Why?
|
| COUP Transcription Factor II | 1 | 2019 | 18 | 0.180 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2005 | 740 | 0.170 |
Why?
|
| Watchful Waiting | 2 | 2015 | 491 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2015 | 4029 | 0.170 |
Why?
|
| Phosphoproteins | 2 | 2005 | 2440 | 0.170 |
Why?
|
| Spermatocele | 1 | 2018 | 9 | 0.170 |
Why?
|
| TRPC Cation Channels | 1 | 2019 | 121 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 8 | 2020 | 5867 | 0.170 |
Why?
|
| Chemokines, CC | 1 | 2020 | 291 | 0.170 |
Why?
|
| Exercise Therapy | 3 | 2017 | 904 | 0.170 |
Why?
|
| Cryopreservation | 1 | 2003 | 664 | 0.170 |
Why?
|
| Lactate Dehydrogenases | 1 | 2018 | 26 | 0.160 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 2542 | 0.160 |
Why?
|
| Treatment Outcome | 18 | 2020 | 62966 | 0.160 |
Why?
|
| Pathology, Clinical | 2 | 2014 | 368 | 0.160 |
Why?
|
| Hemangiopericytoma | 1 | 2018 | 77 | 0.160 |
Why?
|
| Hyphae | 1 | 2018 | 56 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 35342 | 0.160 |
Why?
|
| Indomethacin | 1 | 2019 | 331 | 0.160 |
Why?
|
| Skin Aging | 1 | 2019 | 127 | 0.160 |
Why?
|
| Varicocele | 1 | 2018 | 78 | 0.160 |
Why?
|
| Estradiol | 2 | 2017 | 2021 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 1167 | 0.160 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 135 | 0.160 |
Why?
|
| Robotics | 2 | 2019 | 892 | 0.160 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2019 | 216 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2014 | 4751 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 6313 | 0.160 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2018 | 134 | 0.160 |
Why?
|
| Hypertension | 3 | 2010 | 8455 | 0.160 |
Why?
|
| Mice, Nude | 7 | 2020 | 3689 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2018 | 2948 | 0.160 |
Why?
|
| Restraint, Physical | 2 | 2010 | 193 | 0.150 |
Why?
|
| Gene Amplification | 2 | 2013 | 1062 | 0.150 |
Why?
|
| Boron Compounds | 1 | 2019 | 178 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 2 | 2019 | 577 | 0.150 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 39004 | 0.150 |
Why?
|
| BK Virus | 1 | 2018 | 129 | 0.150 |
Why?
|
| Boston | 6 | 2017 | 9305 | 0.150 |
Why?
|
| Transcription Factors | 4 | 2011 | 12164 | 0.150 |
Why?
|
| Age Factors | 6 | 2017 | 18355 | 0.150 |
Why?
|
| Transients and Migrants | 1 | 2020 | 155 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 250 | 0.150 |
Why?
|
| Carrier Proteins | 4 | 2014 | 5019 | 0.150 |
Why?
|
| Prolactin | 1 | 2019 | 669 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 2 | 2019 | 874 | 0.140 |
Why?
|
| Cell Growth Processes | 3 | 2020 | 400 | 0.140 |
Why?
|
| Blotting, Western | 6 | 2014 | 5180 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11472 | 0.140 |
Why?
|
| PPAR gamma | 2 | 2017 | 493 | 0.140 |
Why?
|
| Pain, Postoperative | 1 | 2006 | 1638 | 0.140 |
Why?
|
| Liver Neoplasms | 4 | 2017 | 4249 | 0.140 |
Why?
|
| beta-Globins | 1 | 2017 | 113 | 0.140 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 196 | 0.140 |
Why?
|
| Sirtuin 1 | 1 | 2017 | 244 | 0.140 |
Why?
|
| TRPM Cation Channels | 1 | 2017 | 140 | 0.140 |
Why?
|
| Drug Labeling | 1 | 2018 | 231 | 0.140 |
Why?
|
| Caspase 12 | 1 | 2015 | 11 | 0.140 |
Why?
|
| Mice | 20 | 2020 | 81045 | 0.140 |
Why?
|
| Endometrial Neoplasms | 1 | 2005 | 1351 | 0.140 |
Why?
|
| Cerebral Palsy | 2 | 2011 | 459 | 0.140 |
Why?
|
| Animals | 29 | 2020 | 168561 | 0.140 |
Why?
|
| Carbamazepine | 1 | 2016 | 229 | 0.140 |
Why?
|
| Leukocyte Disorders | 1 | 2015 | 12 | 0.140 |
Why?
|
| Base Sequence | 3 | 2019 | 12797 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2018 | 358 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 449 | 0.130 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2018 | 713 | 0.130 |
Why?
|
| Candidiasis | 1 | 2018 | 365 | 0.130 |
Why?
|
| Pathology, Surgical | 2 | 2014 | 155 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 689 | 0.130 |
Why?
|
| Transcription Factor CHOP | 1 | 2015 | 73 | 0.130 |
Why?
|
| Reproducibility of Results | 8 | 2020 | 19862 | 0.130 |
Why?
|
| Phthalazines | 1 | 2018 | 361 | 0.130 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 497 | 0.130 |
Why?
|
| Granuloma, Pyogenic | 1 | 2015 | 48 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3691 | 0.130 |
Why?
|
| Recovery of Function | 6 | 2019 | 2924 | 0.130 |
Why?
|
| Dansyl Compounds | 1 | 2014 | 20 | 0.130 |
Why?
|
| HLA-B Antigens | 1 | 2016 | 353 | 0.130 |
Why?
|
| Candida albicans | 1 | 2018 | 394 | 0.130 |
Why?
|
| Cognition | 3 | 2023 | 6722 | 0.130 |
Why?
|
| bcl-Associated Death Protein | 1 | 2015 | 107 | 0.130 |
Why?
|
| ROC Curve | 4 | 2019 | 3528 | 0.130 |
Why?
|
| Hydrocortisone | 3 | 2010 | 1825 | 0.130 |
Why?
|
| Turbinates | 1 | 2015 | 68 | 0.130 |
Why?
|
| Testis | 1 | 2018 | 800 | 0.130 |
Why?
|
| Nose Diseases | 1 | 2015 | 79 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2019 | 644 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 325 | 0.130 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 18006 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 768 | 0.130 |
Why?
|
| Sex Factors | 3 | 2018 | 10392 | 0.130 |
Why?
|
| Rotavirus Vaccines | 1 | 2015 | 61 | 0.130 |
Why?
|
| Time Factors | 11 | 2019 | 40054 | 0.130 |
Why?
|
| Neurofibromin 1 | 1 | 2016 | 196 | 0.120 |
Why?
|
| Radionuclide Imaging | 2 | 2012 | 2027 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 627 | 0.120 |
Why?
|
| In Situ Hybridization | 3 | 2016 | 1950 | 0.120 |
Why?
|
| Androgens | 2 | 2020 | 1271 | 0.120 |
Why?
|
| Herpesvirus 1, Human | 2 | 2010 | 742 | 0.120 |
Why?
|
| Adenosine Triphosphate | 2 | 2020 | 2024 | 0.120 |
Why?
|
| Protective Agents | 1 | 2015 | 156 | 0.120 |
Why?
|
| Rotavirus Infections | 1 | 2015 | 86 | 0.120 |
Why?
|
| Cyclopentanes | 1 | 2014 | 93 | 0.120 |
Why?
|
| Principal Component Analysis | 3 | 2019 | 939 | 0.120 |
Why?
|
| Rotavirus | 1 | 2015 | 109 | 0.120 |
Why?
|
| Deoxycytidine | 1 | 2018 | 824 | 0.120 |
Why?
|
| Imidazoles | 2 | 2019 | 1205 | 0.120 |
Why?
|
| Proteus mirabilis | 1 | 2014 | 25 | 0.120 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 643 | 0.120 |
Why?
|
| SEER Program | 1 | 2019 | 1507 | 0.120 |
Why?
|
| Poland | 1 | 2014 | 184 | 0.120 |
Why?
|
| Risk Factors | 13 | 2020 | 72145 | 0.120 |
Why?
|
| Single-Blind Method | 4 | 2019 | 1589 | 0.120 |
Why?
|
| Fungal Proteins | 1 | 2018 | 912 | 0.120 |
Why?
|
| Phenylthiohydantoin | 1 | 2015 | 192 | 0.120 |
Why?
|
| Telangiectasis | 1 | 2014 | 75 | 0.120 |
Why?
|
| Cystitis | 1 | 2014 | 92 | 0.120 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 491 | 0.120 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 1179 | 0.120 |
Why?
|
| Cytoskeleton | 1 | 2019 | 1185 | 0.120 |
Why?
|
| Students | 1 | 2023 | 1647 | 0.120 |
Why?
|
| Predictive Value of Tests | 7 | 2017 | 15056 | 0.120 |
Why?
|
| Mitochondria | 4 | 2020 | 3520 | 0.120 |
Why?
|
| Skin | 2 | 2019 | 4353 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2013 | 25 | 0.120 |
Why?
|
| Incidence | 4 | 2017 | 20928 | 0.120 |
Why?
|
| Musculoskeletal Diseases | 1 | 2020 | 581 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 6 | 2020 | 6382 | 0.120 |
Why?
|
| Transfection | 5 | 2017 | 5892 | 0.120 |
Why?
|
| Hydrogen Peroxide | 1 | 2017 | 730 | 0.120 |
Why?
|
| Magnetoencephalography | 1 | 2017 | 624 | 0.110 |
Why?
|
| Posterior Horn Cells | 1 | 2013 | 87 | 0.110 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 977 | 0.110 |
Why?
|
| Models, Anatomic | 1 | 2017 | 690 | 0.110 |
Why?
|
| Carcinoma | 2 | 2016 | 2374 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 508 | 0.110 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2013 | 50 | 0.110 |
Why?
|
| Antigens, Surface | 1 | 2017 | 1663 | 0.110 |
Why?
|
| Chromatography, Micellar Electrokinetic Capillary | 1 | 2012 | 3 | 0.110 |
Why?
|
| Sciatica | 1 | 2013 | 98 | 0.110 |
Why?
|
| Combined Modality Therapy | 6 | 2017 | 8621 | 0.110 |
Why?
|
| Cohort Studies | 9 | 2021 | 40450 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 2211 | 0.110 |
Why?
|
| Ultrasonography | 4 | 2018 | 5978 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2017 | 1213 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1417 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2015 | 546 | 0.110 |
Why?
|
| Polymethacrylic Acids | 1 | 2012 | 34 | 0.110 |
Why?
|
| Fibroblasts | 3 | 2019 | 4143 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2015 | 472 | 0.110 |
Why?
|
| Dinoprostone | 2 | 2019 | 600 | 0.110 |
Why?
|
| Prostaglandins | 1 | 2014 | 405 | 0.110 |
Why?
|
| Estrogens | 1 | 2020 | 1562 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 264 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2018 | 1176 | 0.110 |
Why?
|
| Penis | 1 | 2014 | 216 | 0.110 |
Why?
|
| Preoperative Care | 2 | 2015 | 2245 | 0.110 |
Why?
|
| Oncogenes | 1 | 2018 | 1263 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 2861 | 0.110 |
Why?
|
| Phylogeny | 1 | 2020 | 2797 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 2638 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 4 | 2019 | 611 | 0.110 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 934 | 0.100 |
Why?
|
| Mutation | 10 | 2018 | 29717 | 0.100 |
Why?
|
| Laser Coagulation | 1 | 2014 | 326 | 0.100 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 139 | 0.100 |
Why?
|
| Lasers, Solid-State | 1 | 2014 | 169 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2012 | 414 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 638 | 0.100 |
Why?
|
| Down-Regulation | 5 | 2019 | 3001 | 0.100 |
Why?
|
| Haploinsufficiency | 1 | 2013 | 329 | 0.100 |
Why?
|
| Bowen's Disease | 1 | 2011 | 12 | 0.100 |
Why?
|
| Polyvinyls | 1 | 2012 | 157 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2015 | 1583 | 0.100 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2011 | 21 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2015 | 721 | 0.100 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 822 | 0.100 |
Why?
|
| Recurrence | 3 | 2014 | 8333 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2018 | 1613 | 0.100 |
Why?
|
| Psychometrics | 1 | 2020 | 2999 | 0.100 |
Why?
|
| Calcium | 4 | 2019 | 5753 | 0.100 |
Why?
|
| Arsenic Poisoning | 1 | 2011 | 55 | 0.100 |
Why?
|
| Naloxone | 1 | 2013 | 367 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 452 | 0.100 |
Why?
|
| Motor Activity | 2 | 2019 | 2714 | 0.100 |
Why?
|
| Dilazep | 1 | 2010 | 4 | 0.090 |
Why?
|
| Areca | 1 | 2010 | 11 | 0.090 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2010 | 177 | 0.090 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2010 | 17 | 0.090 |
Why?
|
| Nephrectomy | 3 | 2017 | 1049 | 0.090 |
Why?
|
| Neutrophils | 2 | 2015 | 3711 | 0.090 |
Why?
|
| Ribs | 1 | 2012 | 250 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1581 | 0.090 |
Why?
|
| Spermine | 1 | 2010 | 70 | 0.090 |
Why?
|
| Ornithine Decarboxylase | 1 | 2010 | 63 | 0.090 |
Why?
|
| Collagen | 1 | 2019 | 2684 | 0.090 |
Why?
|
| Anticonvulsants | 2 | 2018 | 1914 | 0.090 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 2885 | 0.090 |
Why?
|
| Dipyridamole | 1 | 2010 | 145 | 0.090 |
Why?
|
| Diabetes Insipidus | 1 | 2010 | 151 | 0.090 |
Why?
|
| Case-Control Studies | 7 | 2019 | 21719 | 0.090 |
Why?
|
| Cells, Cultured | 5 | 2019 | 19223 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2017 | 831 | 0.090 |
Why?
|
| Motor Cortex | 1 | 2017 | 984 | 0.090 |
Why?
|
| Ultrasonics | 1 | 2011 | 212 | 0.090 |
Why?
|
| Pain Threshold | 1 | 2013 | 585 | 0.090 |
Why?
|
| Penicillins | 1 | 2012 | 378 | 0.090 |
Why?
|
| Multiprotein Complexes | 2 | 2014 | 1119 | 0.090 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 13019 | 0.090 |
Why?
|
| Electric Stimulation Therapy | 1 | 2015 | 605 | 0.090 |
Why?
|
| Quinolines | 1 | 2014 | 719 | 0.090 |
Why?
|
| Hyperalgesia | 1 | 2013 | 502 | 0.090 |
Why?
|
| Motor Skills | 2 | 2015 | 518 | 0.090 |
Why?
|
| Cystatin B | 1 | 2009 | 11 | 0.090 |
Why?
|
| Obesity | 3 | 2020 | 12705 | 0.090 |
Why?
|
| Glucose Intolerance | 1 | 2013 | 577 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 1 | 2015 | 1144 | 0.090 |
Why?
|
| Caenorhabditis elegans | 1 | 2018 | 1416 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 1899 | 0.090 |
Why?
|
| Physical Fitness | 2 | 2011 | 732 | 0.090 |
Why?
|
| Morphine | 1 | 2013 | 657 | 0.090 |
Why?
|
| Adenine | 1 | 2014 | 936 | 0.090 |
Why?
|
| Adenoma | 1 | 2020 | 2168 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2017 | 4013 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2013 | 562 | 0.080 |
Why?
|
| Phosphorylation | 7 | 2017 | 8436 | 0.080 |
Why?
|
| Arm | 2 | 2010 | 589 | 0.080 |
Why?
|
| Visual Perception | 1 | 2017 | 1417 | 0.080 |
Why?
|
| Hypopituitarism | 1 | 2010 | 254 | 0.080 |
Why?
|
| Cell Survival | 5 | 2018 | 5872 | 0.080 |
Why?
|
| Young Adult | 11 | 2019 | 56350 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2017 | 4024 | 0.080 |
Why?
|
| Adipocytes | 2 | 2020 | 1182 | 0.080 |
Why?
|
| China | 1 | 2014 | 2246 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2015 | 1359 | 0.080 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 3639 | 0.080 |
Why?
|
| Colonic Polyps | 1 | 2013 | 542 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2010 | 442 | 0.080 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 13655 | 0.080 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2010 | 648 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 1847 | 0.080 |
Why?
|
| Pituitary Gland | 1 | 2010 | 665 | 0.080 |
Why?
|
| Muscle Spasticity | 1 | 2008 | 154 | 0.080 |
Why?
|
| Bone Density | 2 | 2011 | 3469 | 0.080 |
Why?
|
| Skull | 1 | 2012 | 810 | 0.080 |
Why?
|
| Finasteride | 1 | 2008 | 89 | 0.070 |
Why?
|
| Piperazines | 1 | 2018 | 2488 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2015 | 2614 | 0.070 |
Why?
|
| Urinary Retention | 1 | 2008 | 110 | 0.070 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 4246 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2015 | 1895 | 0.070 |
Why?
|
| Cisplatin | 4 | 2018 | 1637 | 0.070 |
Why?
|
| Testosterone | 1 | 2017 | 2401 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 1221 | 0.070 |
Why?
|
| Ileum | 1 | 2009 | 565 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2014 | 1548 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 2107 | 0.070 |
Why?
|
| Contrast Media | 1 | 2020 | 5295 | 0.070 |
Why?
|
| Autophagy | 1 | 2014 | 1301 | 0.070 |
Why?
|
| Organ Size | 1 | 2011 | 2253 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2010 | 469 | 0.070 |
Why?
|
| Mobility Limitation | 1 | 2010 | 405 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3584 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2014 | 5975 | 0.070 |
Why?
|
| Quinazolines | 1 | 2013 | 1355 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 2186 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 950 | 0.070 |
Why?
|
| Binding Sites | 1 | 2015 | 6115 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 20086 | 0.070 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 2637 | 0.070 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2014 | 1210 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 4414 | 0.070 |
Why?
|
| United States | 5 | 2019 | 69693 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 2940 | 0.070 |
Why?
|
| Anthropometry | 1 | 2011 | 1350 | 0.070 |
Why?
|
| Seizures | 1 | 2018 | 2851 | 0.070 |
Why?
|
| Analysis of Variance | 5 | 2018 | 6365 | 0.070 |
Why?
|
| Cell Respiration | 2 | 2020 | 200 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2010 | 2938 | 0.070 |
Why?
|
| 19-Iodocholesterol | 1 | 2005 | 4 | 0.070 |
Why?
|
| Enuresis | 1 | 2005 | 47 | 0.070 |
Why?
|
| Edema | 1 | 2010 | 790 | 0.070 |
Why?
|
| Feedback, Physiological | 2 | 2019 | 479 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 1525 | 0.070 |
Why?
|
| Sirolimus | 1 | 2013 | 1562 | 0.070 |
Why?
|
| Afferent Pathways | 2 | 2017 | 302 | 0.070 |
Why?
|
| HT29 Cells | 1 | 2005 | 200 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2019 | 3258 | 0.070 |
Why?
|
| Curcumin | 1 | 2006 | 95 | 0.070 |
Why?
|
| 3T3-L1 Cells | 2 | 2020 | 197 | 0.060 |
Why?
|
| Insulin-Secreting Cells | 1 | 2013 | 891 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2010 | 1849 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 995 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 3 | 2017 | 1655 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2019 | 4211 | 0.060 |
Why?
|
| Oncolytic Virotherapy | 1 | 2010 | 490 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2020 | 4229 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 14720 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2013 | 3667 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 8300 | 0.060 |
Why?
|
| Catecholamines | 1 | 2005 | 387 | 0.060 |
Why?
|
| Logistic Models | 3 | 2019 | 13403 | 0.060 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 1813 | 0.060 |
Why?
|
| Rats | 3 | 2015 | 24265 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2016 | 1707 | 0.060 |
Why?
|
| Adrenal Gland Diseases | 1 | 2005 | 138 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2018 | 3111 | 0.060 |
Why?
|
| Urination Disorders | 1 | 2005 | 241 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 5163 | 0.060 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2006 | 732 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 3504 | 0.060 |
Why?
|
| Epithelial Cells | 3 | 2011 | 3678 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2011 | 2751 | 0.060 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 440 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2019 | 320 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2266 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 2276 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2017 | 4030 | 0.060 |
Why?
|
| Child | 8 | 2020 | 77478 | 0.060 |
Why?
|
| Naphthyridines | 2 | 2014 | 118 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2020 | 1791 | 0.050 |
Why?
|
| Computational Biology | 2 | 2019 | 3518 | 0.050 |
Why?
|
| Ultraviolet Rays | 2 | 2019 | 1059 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 24913 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2018 | 1727 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2009 | 1638 | 0.050 |
Why?
|
| Trail Making Test | 1 | 2022 | 57 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2018 | 245 | 0.050 |
Why?
|
| Proteomics | 1 | 2015 | 3618 | 0.050 |
Why?
|
| Virus Replication | 1 | 2010 | 2531 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 18112 | 0.050 |
Why?
|
| Cholesterol | 1 | 2011 | 2895 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2012 | 9846 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2010 | 2466 | 0.050 |
Why?
|
| Cell Division | 1 | 2009 | 4564 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 3328 | 0.050 |
Why?
|
| Radiography | 2 | 2020 | 7010 | 0.050 |
Why?
|
| DNA | 1 | 2015 | 7289 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 3585 | 0.050 |
Why?
|
| Clinical Protocols | 2 | 2017 | 1459 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 5171 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2005 | 648 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2018 | 1615 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2020 | 1725 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 2354 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2006 | 1961 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2020 | 40955 | 0.050 |
Why?
|
| Neurofibromatoses | 1 | 2005 | 299 | 0.050 |
Why?
|
| RNA Splicing | 2 | 2016 | 907 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2005 | 1526 | 0.050 |
Why?
|
| Insulin | 3 | 2013 | 6575 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2010 | 1368 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2012 | 2527 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 3800 | 0.050 |
Why?
|
| 17-Hydroxycorticosteroids | 1 | 2020 | 40 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2017 | 2715 | 0.050 |
Why?
|
| Patient Selection | 2 | 2012 | 4214 | 0.050 |
Why?
|
| Adolescent | 7 | 2020 | 85649 | 0.050 |
Why?
|
| Moving and Lifting Patients | 1 | 2020 | 18 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2018 | 7721 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2011 | 2706 | 0.040 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 1707 | 0.040 |
Why?
|
| Neoplasms | 2 | 2020 | 21596 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 2014 | 0.040 |
Why?
|
| Retinoid X Receptors | 1 | 2019 | 93 | 0.040 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2020 | 83 | 0.040 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2019 | 70 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2020 | 408 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2013 | 625 | 0.040 |
Why?
|
| Carcinogenicity Tests | 1 | 2018 | 41 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2019 | 235 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 12071 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 697 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2019 | 379 | 0.040 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2019 | 249 | 0.040 |
Why?
|
| Vimentin | 1 | 2018 | 261 | 0.040 |
Why?
|
| Imitative Behavior | 1 | 2017 | 33 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 331 | 0.040 |
Why?
|
| Nitriles | 2 | 2015 | 952 | 0.040 |
Why?
|
| Proteins | 2 | 2010 | 6096 | 0.040 |
Why?
|
| Stroop Test | 1 | 2017 | 62 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 468 | 0.040 |
Why?
|
| Phosphorus | 1 | 2019 | 338 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 217 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 1782 | 0.040 |
Why?
|
| Headache | 1 | 2005 | 1219 | 0.040 |
Why?
|
| Dihydrotestosterone | 1 | 2017 | 188 | 0.040 |
Why?
|
| Cell Line | 3 | 2018 | 15994 | 0.040 |
Why?
|
| Acute Disease | 2 | 2020 | 7141 | 0.040 |
Why?
|
| Allopurinol | 1 | 2018 | 185 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2018 | 195 | 0.040 |
Why?
|
| Cell Transformation, Viral | 1 | 2018 | 565 | 0.040 |
Why?
|
| Diabetes, Gestational | 1 | 2006 | 1184 | 0.040 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 1889 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2018 | 1675 | 0.040 |
Why?
|
| Texas | 1 | 2017 | 392 | 0.040 |
Why?
|
| RNA Probes | 1 | 2016 | 113 | 0.040 |
Why?
|
| Kallikreins | 1 | 2018 | 258 | 0.040 |
Why?
|
| Protein Stability | 1 | 2018 | 556 | 0.030 |
Why?
|
| Functional Laterality | 2 | 2017 | 2290 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2017 | 210 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 228 | 0.030 |
Why?
|
| Integrases | 1 | 2018 | 533 | 0.030 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2016 | 79 | 0.030 |
Why?
|
| Thailand | 1 | 2016 | 296 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2002 | 569 | 0.030 |
Why?
|
| Pericytes | 1 | 2018 | 291 | 0.030 |
Why?
|
| Bicycling | 1 | 2017 | 176 | 0.030 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 301 | 0.030 |
Why?
|
| Aging | 1 | 2015 | 8626 | 0.030 |
Why?
|
| Social Participation | 1 | 2017 | 172 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2019 | 865 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 2043 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2018 | 834 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 5304 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2005 | 2410 | 0.030 |
Why?
|
| Lung | 1 | 2014 | 9826 | 0.030 |
Why?
|
| Cell Nucleolus | 1 | 2015 | 166 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7276 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2019 | 780 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2018 | 667 | 0.030 |
Why?
|
| Virulence | 1 | 2018 | 1328 | 0.030 |
Why?
|
| Femur | 2 | 2011 | 1297 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 275 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2017 | 504 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3769 | 0.030 |
Why?
|
| Quality of Life | 2 | 2017 | 12730 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 9639 | 0.030 |
Why?
|
| Reference Values | 2 | 2011 | 4982 | 0.030 |
Why?
|
| Internationality | 1 | 2019 | 1002 | 0.030 |
Why?
|
| Gene Expression | 3 | 2015 | 7790 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 589 | 0.030 |
Why?
|
| Genotype | 2 | 2019 | 12946 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2015 | 9144 | 0.030 |
Why?
|
| Resorcinols | 1 | 2013 | 38 | 0.030 |
Why?
|
| Desmin | 1 | 2013 | 130 | 0.030 |
Why?
|
| National Health Programs | 1 | 2016 | 445 | 0.030 |
Why?
|
| Malondialdehyde | 1 | 2013 | 104 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2013 | 303 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 1875 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2013 | 126 | 0.030 |
Why?
|
| Antigens | 1 | 2018 | 1462 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 11695 | 0.030 |
Why?
|
| Breath Tests | 1 | 2014 | 276 | 0.030 |
Why?
|
| Anions | 1 | 2012 | 133 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2006 | 12017 | 0.030 |
Why?
|
| Video Recording | 1 | 2017 | 944 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 2013 | 352 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2013 | 180 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2019 | 2215 | 0.030 |
Why?
|
| Methylation | 1 | 2015 | 1107 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 10943 | 0.030 |
Why?
|
| Cations | 1 | 2012 | 231 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 608 | 0.030 |
Why?
|
| Static Electricity | 1 | 2012 | 267 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2020 | 1806 | 0.030 |
Why?
|
| Triage | 1 | 2018 | 977 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2018 | 2224 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 1342 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2012 | 264 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 5662 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 892 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2013 | 216 | 0.030 |
Why?
|
| Research Design | 2 | 2017 | 5979 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2013 | 357 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 2020 | 1472 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 1581 | 0.020 |
Why?
|
| Metabolome | 1 | 2018 | 881 | 0.020 |
Why?
|
| Lumbar Vertebrae | 2 | 2011 | 1844 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2013 | 574 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1887 | 0.020 |
Why?
|
| Lipoxins | 1 | 2014 | 411 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 441 | 0.020 |
Why?
|
| Hemiplegia | 1 | 2011 | 135 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 971 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 2085 | 0.020 |
Why?
|
| Marital Status | 1 | 2012 | 437 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2014 | 670 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2010 | 65 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2014 | 1683 | 0.020 |
Why?
|
| Butadienes | 1 | 2010 | 110 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 2010 | 173 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 1190 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2019 | 3199 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2011 | 199 | 0.020 |
Why?
|
| Sciatic Nerve | 1 | 2013 | 609 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 434 | 0.020 |
Why?
|
| Ribonucleotide Reductases | 1 | 2010 | 77 | 0.020 |
Why?
|
| Referral and Consultation | 2 | 2013 | 3527 | 0.020 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2010 | 129 | 0.020 |
Why?
|
| Benzamides | 1 | 2015 | 1378 | 0.020 |
Why?
|
| Workflow | 1 | 2014 | 846 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 2156 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2013 | 1902 | 0.020 |
Why?
|
| Cyclin B | 1 | 2009 | 108 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2016 | 3587 | 0.020 |
Why?
|
| Caspases | 1 | 2013 | 928 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 898 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1769 | 0.020 |
Why?
|
| Seasons | 1 | 2015 | 1492 | 0.020 |
Why?
|
| Microscopy | 1 | 2014 | 903 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2017 | 1402 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2009 | 112 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2018 | 2205 | 0.020 |
Why?
|
| Calcaneus | 1 | 2010 | 138 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 692 | 0.020 |
Why?
|
| Antioxidants | 1 | 2017 | 1659 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2018 | 6452 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2009 | 220 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2010 | 380 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 2593 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2009 | 821 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1786 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 2417 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 430 | 0.020 |
Why?
|
| Muscles | 1 | 2013 | 1617 | 0.020 |
Why?
|
| Arsenic | 1 | 2011 | 328 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2013 | 1167 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2721 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 5519 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 1969 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2010 | 808 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2013 | 728 | 0.020 |
Why?
|
| Cyclin D | 1 | 2007 | 71 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 2552 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 944 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2007 | 135 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 434 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2011 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2009 | 15244 | 0.020 |
Why?
|
| Reaction Time | 1 | 2013 | 2092 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 411 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2018 | 53187 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2010 | 466 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2013 | 1243 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 1989 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2009 | 709 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 2876 | 0.020 |
Why?
|
| CpG Islands | 1 | 2011 | 1170 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2009 | 453 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1434 | 0.020 |
Why?
|
| Infant | 2 | 2020 | 35070 | 0.020 |
Why?
|
| Lasers | 1 | 2010 | 952 | 0.020 |
Why?
|
| DNA Damage | 1 | 2015 | 2423 | 0.020 |
Why?
|
| Neuropeptides | 1 | 2011 | 942 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2013 | 1882 | 0.020 |
Why?
|
| Exercise | 1 | 2022 | 5611 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 941 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2007 | 390 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 2183 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 2615 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 3058 | 0.020 |
Why?
|
| Pregnancy | 1 | 2006 | 29087 | 0.020 |
Why?
|
| Algorithms | 1 | 2005 | 13853 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5062 | 0.020 |
Why?
|
| Length of Stay | 1 | 2018 | 6294 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 987 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 647 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 14554 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 4742 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 1940 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 1726 | 0.020 |
Why?
|
| Luciferases | 1 | 2006 | 733 | 0.020 |
Why?
|
| Body Height | 1 | 2010 | 1574 | 0.010 |
Why?
|
| Spin Labels | 1 | 2005 | 332 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2013 | 3199 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 731 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2009 | 3127 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 2028 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4553 | 0.010 |
Why?
|
| Prevalence | 1 | 2020 | 15194 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 4187 | 0.010 |
Why?
|
| Registries | 1 | 2018 | 8077 | 0.010 |
Why?
|
| RNA, Nuclear | 1 | 2002 | 30 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2009 | 2713 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2006 | 1547 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2005 | 704 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 3038 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2009 | 1659 | 0.010 |
Why?
|
| Aspirin | 1 | 2014 | 3278 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2005 | 701 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 10163 | 0.010 |
Why?
|
| Epilepsy | 1 | 2016 | 3301 | 0.010 |
Why?
|
| Keratins | 1 | 2002 | 515 | 0.010 |
Why?
|
| Drug Design | 1 | 2006 | 1078 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 2749 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2010 | 1932 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 5851 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 3133 | 0.010 |
Why?
|
| Software | 1 | 2014 | 4434 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12220 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2002 | 2255 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2002 | 908 | 0.010 |
Why?
|
| Epithelium | 1 | 2004 | 1680 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15494 | 0.010 |
Why?
|
| Protons | 1 | 2005 | 1126 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2005 | 1839 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2020 | 25575 | 0.010 |
Why?
|
| Brain | 1 | 2005 | 26343 | 0.010 |
Why?
|
| Pyridines | 1 | 2010 | 2818 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10372 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7901 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 1640 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2002 | 1040 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 5522 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2003 | 1538 | 0.010 |
Why?
|
| Hospitalization | 1 | 2015 | 10232 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 21821 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3920 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 17400 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 4933 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2002 | 2899 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 3465 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 8925 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 9274 | 0.000 |
Why?
|